1. Background {#sec0005}
=============

Influenza results in significant morbidity and mortality in the U.S and worldwide [@bib0005], and this is exacerbated by bacterial co-infections during both seasonal and pandemic influenza years [@bib0010], [@bib0015], [@bib0020]. During the most severe influenza pandemic recorded, in 1918--1919, when an estimated 675,000 people died in the United States [@bib0025], [@bib0030], epidemiologic, clinical and pathologic data indicate that the majority of influenza patients died from bacterial pneumonia rather than from the influenza virus itself. Bacterial co-infections should thus be studied in order to devise effective preventative and therapeutic strategies [@bib0010], [@bib0015], [@bib0035].

Influenza virus has been shown to have complex effects on the human lung, priming the respiratory tract for synergistic pathogenesis with a bacterial co-infection [@bib0040]. Morbidity and mortality are increased when bacterial pneumonia complicates influenza infection as compared with bacterial pneumonia in the absence of influenza infection [@bib0045], [@bib0050].

During the 1918 and 1968--1969 pandemics, *Streptococcus pneumoniae* was likely the most common co-pathogen [@bib0015], [@bib0055]. In the 1957--1958 pandemic, many reports identified *Staphylococcus aureus* as the most frequently cultured co-pathogen [@bib0015], [@bib0060], [@bib0065]. More recently *S. aureus* has been increasingly found in cases of fulminant pneumonia complicating influenza infection [@bib0070], [@bib0075]. *Haemophilus influenzae*, with the introduction of the *H. influenzae* type B conjugate vaccine in 1985 [@bib0080], and *Streptococcus pyogenes* have decreased in prevalence over time [@bib0085]. Vaccination, novel antibiotics, and probably more importantly, viral or bacterial strain-related differences account for shifts in etiology of the most common bacterial co-infections [@bib0040].

A novel pandemic influenza A strain, influenza A (H1N1) pdm09, emerged in 2009. Reported rates of bacterial co-infection among severely ill patients varied between 17.5% and 25% for community-acquired influenza patients in the 2009--2010 season [@bib0090], [@bib0095] and 33% in a study of combined community-acquired and hospital-acquired influenza patients [@bib0100]. In these and other studies the most common community-acquired pathogens included *S. pneumoniae* and then *S. aureus* [@bib0050]. The risk of co-infection and spectrum of bacterial species has not been studied during the 2013--2014 season, the first postpandemic year in which influenza A (H1N1) pdm was the predominant circulating influenza strain.

2. Objectives {#sec0010}
=============

We recently completed a retrospective study of 507 patients with severe influenza treated in intensive care units (ICUs) of 33 U.S. hospitals during the 2013--2014 influenza season [@bib0105]. The objectives of the present study were to evaluate bacterial and viral co-infection in this cohort, to describe the spectrum of co-infections and to determine their clinical impact.

3. Study design {#sec0015}
===============

We performed a retrospective cohort study of all patients with laboratory confirmed influenza A and/or influenza B infection who were diagnosed with influenza during an ICU stay or within 30 days prior to an ICU admission between September 1, 2013 and April 1, 2014 at 33 U.S. study sites that made up the Severe H1N1 Influenza Consortium (SHIC) [@bib0105]. Laboratory testing may have been with a PCR-based test, a rapid test or viral culture. Complete laboratory data were accessed from infection control records, an enterprise data warehouse or directly from the clinical microbiology laboratory. Institutional review boards approved the study at each of the participating sites.

3.1. Data collected {#sec0020}
-------------------

Data for this study were abstracted by a physician from each center's electronic health record (EHR) and entered into a REDCap database [@bib0110]. Data abstracted and study site information were previously described [@bib0105].

Bacterial co-infection was defined in patients having one or more isolates obtained from a blood culture and/or a pleural fluid, sputum, tracheal or bronchoscopic sample if the isolate was a pathogen thought to be causing a true infection in the opinion of the treating physician and if the isolate was collected within 30 days of ICU admission or present on arrival to the ICU. Viral co-infection was defined in patients having a positive PCR or appropriate antibody test for a viral pathogen other than influenza. Bacterial co-infections cultured within 48 h of hospital admission were defined as community-acquired; those cultured after 48 h were considered to be hospital-acquired. Bacterial identification and susceptibility testing were performed by methods determined by institutional guidelines. For all patients, management was according to institutional practices.

3.2. Statistical analysis {#sec0025}
-------------------------

STATA v12 (College Station, TX: StataCorp LP) was used for all analyses. Outliers were reexamined in the EHR to ensure data accuracy. No subject with outlying values was excluded from any analysis. Descriptive statistics were tabulated. Bivariable analyses were used to compare potential risk factors for bacterial co-infection diagnosed during the 30 days after ICU admission or present on admission. A multivariable logistic regression model was developed to determine which of the variables significantly associated in bivariable analyses (p \< 0.05) were independently associated with co-infection. Further multivariable analysis was used to predict risk of death among co-infected patients and also to assess resource utilization accounting for admission SOFA score.

4. Results {#sec0030}
==========

Five hundred and seven patients with severe influenza were admitted to ICUs at one of the 33 U.S. hospitals participating in the SHIC study in 2013--2014. In this cohort influenza A (H1N1) pdm09 caused 311 (61.3%) infections, and influenza A virus that were not subtyped caused 170 (33.5%) additional infections. Other influenza strains caused 5.2% of infections ([Table 1](#tbl0005){ref-type="table"} ).Table 1Characteristics of 507 patients with severe influenza infection in the U.S. diagnosed between September 1, 2013 and April 1, 2014, comparing adult and pediatric patients.Table 1Characteristics[a](#tblfn0005){ref-type="table-fn"}Adults (N = 444) No. (%)Children (N = 63) No. (%)SexFemale223 (50.2)28 (44.4)Age group0--4 yr--39 (61.9)5--9 yr--10 (2.0)10--17 yr--14 (2.8)18--49 yr156 (30.8)--50--64 yr185 (36.5)--≥65 yr103 (20.3)--  Influenza type and subtypeA---H1N1 pdm2009274 (61.7)37 (58.7)A---subtype not specified150 (33.8)20 (31.7)A---H1 subtype not pdm20096 (1.4)2 (3.2)A---H33 (0.7)2 (3.2)B11 (2.5)2 (3.2)  Initial influenza diagnostic test (N = 506)Polymerase chain reaction369 (83.1)38/62 (61.3)Rapid influenza test61 (13.7)18/62 (29.0)Viral culture7 (1.6)0 (0)Other7 (1.6)6/62 (9.7)  Influenza vaccineReceived 2013--14 vaccine (N = 258)108/210 (51.4)18/48 (37.5)  Respiratory bacterial co-infectionInfection at any point during hospitalization103 (23.2)11 (17.5)Infection cultured within 48 h of hospital admission56 (12.6)6 (9.5)Infection cultured greater than 48 h after hospital admission47 (10.6)5 (7.9)  Respiratory viral co-infectionInfection at any point during hospitalization13 (2.9)10 (15.9)  AntibacterialsReceived antibiotics418 (94.1)49 (77.8)Placed on empiric Community-Acquired Pneumonia therapy[b](#tblfn0010){ref-type="table-fn"}146 (32.9)10 (15.9)Placed on empiric Hospital-Acquired Pneumonia therapy[c](#tblfn0015){ref-type="table-fn"}219 (49.3)9 (14.3)  AntiviralsReceived after symptom onset421 (94.8)57 (90.5)Initiated ≤48 h after symptom onset (N = 474)110/417 (26.4)32/57 (56.1)  Died93 (20.9)4 (6.4)[^1][^2][^3]

There were 444 adult and 63 pediatric subjects. Baseline characteristics are displayed in [Table 1](#tbl0005){ref-type="table"}. Bacterial co-infection was present in 114 (22.5%) subjects, comprising 23.2% of adult and 17.5% of pediatric subjects. Sixty two (12.2%) subjects developed community-acquired bacterial co-infection and 52 (10.3%) subjects developed hospital-acquired bacterial co-infection. Of the patients who developed community-acquired and hospital-acquired bacterial co-infections, 15/62 (24.2%) and 14/52 (26.9%), respectively, had no significant comorbid conditions.

There were 129 total bacterial isolates cultured from the 507 patients in our cohort ([Table 2](#tbl0010){ref-type="table"} ), including 26 (20.2%) methicillin resistant *S. aureus* (MRSA), 21 (16.3%) methicillin susceptible *S. aureus* (MSSA), 20 (15.5%) *Enterobacteriaceae* species, 18 (14.0%) *Pseudomonas* species, 7 (5.4%) *S. pneumoniae* and 37 (28.7%) other species ([Table 2](#tbl0010){ref-type="table"}). *S. aureus* susceptibilities are displayed in [Fig. 1](#fig0005){ref-type="fig"} . Of the MRSA isolates, all were susceptible to trimethoprim-sulfamethoxazole, 96.2% to tetracycline, 56% to clindamycin and 20.8% to erythromycin.Table 2Bacterial co-pathogens among 507 patients with severe influenza infection in the U.S. diagnosed between September 1, 2013 and April 1, 2014 by source of isolate.Table 2Bacterial co-pathogenFrequency; N (%)Blood isolates; N (%)Sputum isolates; N (%)Blood and Sputum isolates; N (%)Methicillin resistant *Staphylococcus aureus*26 (20.2)3 (11.5)18 (69.2)5 (19.2)Methicillin susceptible *Staphylococcus aureus*21 (16.3)3 (14.3)17 (81.0)1 (4.8)*Enterobacteriaceae*20 (15.5)2 (10.0)17 (85.0)1 (5.0)*Pseudomonas* sp.18 (14.0)2 (11.1)16 (88.9)*Streptococcus pneumoniae*7 (5.4)4 (57.1)2 (28.6)1 (14.3)*Enterococcus* sp.5 (3.9)5 (100)*Acinetobacter baumannii*4 (3.1)4 (100)*Moraxella catarrhalis*4 (3.1)4 (100)Viridans streptococci4 (3.1)4 (100)*Haemophilus influenzae*3 (2.3)3 (100)Coagulase-negative staphylococci3 (2.3)3 (100)*Stenotrophomonas maltophilia*3 (2.3)3 (100)β-hemolytic streptococci (Not Group A or B)2 (1.6)1 (50)1 (50)*Burkholderia* sp.2 (1.6)2 (100)*Corynebacterium* sp.2 (1.6)2 (100)*Streptococcus pyogenes*2 (1.6)1 (50)1 (50)*Bordetella bronchiseptica*1 (0.8)1 (100)*Sphingomonas paucimobilis*1 (0.8)1 (100)*Streptococcus agalactiae*1 (0.8)1 (100)[^4]Fig. 1Antibiogram of *Staphylococcus aureus* isolates (n = 47) from co-infections, showing the percent that were resistant or intermediate to selected antibacterial drugs from 47 patients with severe influenza in the U.S. between September 1, 2013 and April 1, 2014.Fig. 1

*S. aureus* was the most prevalent species among both community- (43.7%) and hospital-acquired (27.6%) pathogens ([Table 3](#tbl0015){ref-type="table"} and [Fig. 2](#fig0010){ref-type="fig"} ). The prevalence of *S. aureus* was lower among hospital-acquired co-infections as compared with community-acquired co-infections. In contrast, the prevalence of *Enterobacteriaceae* and *Pseudomonas* sp. was higher among hospital-acquired bacterial co-infections (19.0% and 19.0%, respectively) as compared to community-acquired bacterial co-infections (12.7% and 9.9%, respectively). *S. pneumoniae*, *H. influenzae* and *S. pyogenes* were not isolated among hospital-acquired pathogens but were present among community-acquired co-infections (9.9%, 4.2%, and 2.8%), respectively.Table 3Bacterial co-pathogens among 507 adult and pediatric patients with severe influenza infection in the U.S. diagnosed between September 1, 2013 and April 1, 2014 by site at acquisition (community or hospital acquired) and presence or absence of respiratory comorbidities.Table 3Age GroupCo-PathogenCommunity acquiredHospital acquiredPresence of respiratory comorbidities; N (%)Absence of respiratory comorbidities; N (%)Presence of respiratory comorbidities; N (%)Absence of respiratory comorbidities; N (%)Adults (N = 117)Methicillin resistant *Staphylococcus aureus*5/28 (17.8)11/38 (28.9)3/23 (13.0)5/28 (17.9)Methicillin susceptible *Staphylococcus aureus*6/28 (21.4)6/38 (15.8)2/23 (8.7)4/28 (14.3)*Enterobacteriaceae*5/28 (17.9)4/38 (10.5)5/23 (21.7)5/28 (17.9)*Pseudomonas* sp.4/28 (14.3)3/38 (7.9)6/23 (26.1)3/28 (10.7)*Streptococcus pneumoniae*5/38 (13.2)*Enterococcus* sp.1/38 (2.6)1/23 (4.3)2/28 (7.1)*Acinetobacter baumannii*1/38 (2.6)1/23 (4.3)2/28 (7.1)*Moraxella catarrhalis*2/28 (7.1)1/38 (2.6)Viridans streptococci1/38 (2.6)2/23 (8.7)1/28 (3.6)*Haemophilus influenzae*2/28 (7.1)1/38 (2.6)Coagulase-negative staphylococci1/28 (3.6)2/28 (7.1)*Stenotrophomonas maltophilia*3/23 (13.0)β-hemolytic streptococci (Not Group A or B)2/38 (5.3)*Burkholderia* sp.2/28 (7.1)*Corynebacterium* sp.1/28 (3.6)1/38 (2.6)*Streptococcus pyogenes*1/28 (3.6)1/38 (2.6)*Bordetella bronchiseptica*1/28 (3.6)*Sphingomonas paucimobilis*1/28 (3.6)*Streptococcus agalactiae*1/28 (3.6)  Children (N = 12)Methicillin resistant *Staphylococcus aureus*1/4 (25.0)1/6 (16.7)Methicillin susceptible *Staphylococcus aureus*1/1 (100.0)1/4 (25.0)1/6 (16.7)*Enterobacteriaceae*1/6 (16.7)*Pseudomonas* sp.1/1 (100.0)1/6 (16.7)*Streptococcus pneumoniae*2/4 (50.0)*Enterococcus* sp.1/6 (16.7)*Moraxella catarrhalis*1/6 (16.7)Fig. 2Percentage of community-acquired and hospital-acquired co-infections attributed to *Staphylococcus aureus*, *Enterobacteriaceae* and *Pseudomonas* sp. among 507 patients with severe influenza in the U.S. between September 1, 2013 and April 1, 2014.Fig. 2

Patient characteristics associated with development of bacterial co-infection among adults (\>17 years of age) in bivariable analyses are shown in [Table 4](#tbl0020){ref-type="table"} . The number of children in our cohort who developed a bacterial co-infection was too small to assess for risk factors for co-infection. Characteristics independently associated with the development of bacterial co-infection in adults included absence of cardiovascular disease (OR 0.41 \[0.23--0.73\], p = 0.003), leukocytosis at ICU admission (\>11 K/μl, OR 3.7 \[2.2--6.2\], p \< 0.001; reference: normal WBC 3.5--11 K/μl) and elevated SOFA score at ICU admission (for each increase by 1 in SOFA score, OR 1.1 \[1.0--1.2\], p = 0.001).Table 4Patient characteristics associated with bacterial co-infection among 444 adult patients with severe influenza infection in the U.S. between September 1, 2013 and April 1, 2014: Results of bivariable analyses and a multivariable logistic regression model.[a](#tblfn0020){ref-type="table-fn"}Table 4Characteristic[b](#tblfn0025){ref-type="table-fn"}Not co-infected; N = 341 (%)Co-infected; N = 103 (%)Univariable; P valueMultivariable; odds ratio (95% CI), P valueAge, years18--49117 (34.3)39 (39)0.69050--64142 (41.6)43 (41.8)\>6582 (24.1)21 (20.4)  SexFemale171 (50.2)52 (50.5)0.952Male170 (49.9)51 (49.5)  Race (N = 393)White184/298 (61.7)58/95 (61.1)0.404Black92/298 (30.9)26/95 (27.4)Other22/298 (7.4)11/95 (11.6)  Ethnicity\
(N = 403)Hispanic43/308 (14.0)14/95 (14.7)0.850Not Hispanic265/308 (86.0)81/95 (85.3)  Body mass index, kg/m^2^ (N = 439)\>30182/339 (53.7)51/100 (51.0)0.89130--39 (obese)108/339 (31.9)34/100 (34.0)≥40 (morbidly obese)49/339 (14.5)15/100 (15.0)  Admission to a hospital or SNF/LTEC stay in the prior yearYes117 (34.3)33 (32.0)0.251No133 (39.0)34 (33.0)Unknown91 (26.7)36 (35.0)  ComorbiditiesAsthma64 (18.8)17 (16.5)0.602COPD or other chronic lung disease (N = 443)81/340 (23.8)25 (24.3)0.914Cardiovascular disease110 (31.4)19 (18.5)0.0070.41 (0.23--0.73), 0.003Diabetes mellitus108 (31.7)31 (30.1)0.763Chronic kidney disease60 (17.6)12 (11.7)0.151Liver disease20 (5.9)9 (8.7)0.301Malignancy, received chemotherapy in past 6 mo19 (5.6)8 (7.8)0.414HIV infection8 (2.3)1 (1.0)0.385Dementia11 (3.2)3 (2.9)0.873Other neurologic diseases38 (11.1)11 (10.7)0.895History of transplant31 (9.1)5 (4.9)0.167Received steroid within the past month21 (6.2)11 (10.7)0.120Received biologics within the past month (N = 443)8/340 (2.4)1 (1.0)0.391FTT or malnutrition (N = 443)13/340 (3.8)5 (4.9)0.642Current smoker (N = 442)107 (31.4)24/101 (23.8)0.141  White blood cell count on admission to ICU, K/uL (N = 443)\>11 (Leukocytosis)102/340 (30.0)52 (50.5)\<0.00013.7 (2.2--6.2),\<0.0013.5--11 (Normal)211/340 (62.1)36 (35.0)Reference\<3.5 (Leukopenia)27/340 (7.9)15 (14.6)2.0 (0.94--4.4), 0.070  SOFA score on admission to ICU; mean (sd) (N = 440)[c](#tblfn0030){ref-type="table-fn"}7.5 (4.3)9.3 (4.2)0.00011.1 (1.0--1.2), 0.001  Initial chest X-ray quadrants with infiltrate[d](#tblfn0035){ref-type="table-fn"}≥2172 (50.4)61 (59.2)0.118[^5][^6][^7][^8][^9]

Of the patients co-infected with a bacterial pathogen, 34 (29.8%) died, and of the patients not co-infected with a bacterial pathogen, 63 (16.0%) died. Bacterial co-infected patients were significantly more likely to die (OR 2.2 \[1.4--3.6\], p = 0.001) than patients not co-infected with a bacterial pathogen in univariable analysis. When controlling for disease severity by the SOFA score, patients co-infected were still more likely to die (OR 1.8 \[1.1--3.1\], p = 0.024). Patients co-infected with *S. aureus* were not more likely to die than patients with other bacterial co-infections in univariable analysis (OR 1.1 \[0.49--2.5\], p = 0.8) or when controlling for SOFA score (OR 1.1 \[0.5--2.7\], p = 0.75). Patients who had a bacterial co-infection had a longer hospital stay (26.5 days vs 13.6 days; p \< 0.0001), had a longer ICU stay (14.6 days vs 7.9 days; p = 0.003) and had a greater delay in the initiation of administration of an antiviral (6.9 days vs 5.3 days; p = 0.02) than patients without bacterial co-infection. Each of these last three outcomes were not significant, however, when controlling for the admission SOFA score.

Autopsy data, available for only 12 subjects, revealed that four (25%) had bacterial superinfection, of whom three had known bacterial co-infection from cultures obtained prior to death (all with *S. aureus*). One did not have a causative organism cultured.

Viral respiratory co-infections were identified in 23/507 (4.5%) of patients. The viral pathogens included 8/23 (34.8%) rhinovirus/enterovirus, 4/23 (17.4%) respiratory syncytial virus, 3/23 (13.0%) each adenovirus, coronavirus and parainfluenza virus and 2/23 (8.7%) human metapneumovirus. Patients with viral co-infection were more likely to have leukemia (p = 0.004), lymphoma or myeloma (p \< 0.001), a history of transplantation (p \< 0.001) and to have received chemotherapy in the previous six months (p = 0.007) in bivariable analysis. Nine (39.1%) patients with viral co-infection died. Patients with a viral co-infection were significantly more likely to die (OR 3.1 \[1.3--7.4\], p = 0.010) than patients without a viral co-infection in bivariable analysis. When controlling for underlying comorbidities of leukemia, lymphoma, myeloma and transplantation, patients with viral co-infection were not significantly more likely to die (OR 0.78 \[−0.13 to 1.7\], p = 0.094).

5. Discussion {#sec0035}
=============

In patients with severe influenza infection during 2013--2014, the first postpandemic season in the U.S. in which influenza A (H1N1) pdm09 was the predominant circulating influenza strain, respiratory co-infections were common, were associated with higher mortality. They resulted in increased resource allocation, as defined by longer hospital and ICU stay, although this was not significant when accounting for admission SOFA score. In this study of 507 patients with severe influenza, 22.5% had bacterial co-infection and 4.5% had viral co-infection. Of the 99 patients who died, more than one-third had a bacterial co-infection. *S. aureus* was the most prevalent species causing respiratory bacterial co-infection, and MRSA was the most common community-acquired pathogen. This supports the idea that *S. aureus* has a synergistic relationship with influenza A (H1N1) pdm09, even for people in the community. Patients with bacterial co-infection were less likely to have cardiovascular disease, were more likely to have leukocytosis on ICU admission and tended to have a higher ICU admission SOFA score.

In our cohort, among the 22.5% of patients with a bacterial co-infection, 12.2% had community-acquired and 10.3% had hospital-acquired co-infections. Our rates were lower than those reported in the 2009--2010 season. During that pandemic year, rates of 17.5--25% for community-acquired co-infections and 33% for combined community- and hospital-acquired co-infections were reported although the criteria for defining a co-infected patient varied by study [@bib0090], [@bib0095], [@bib0100]. Four (25%) out of 12 autopsies in our cohort showed evidence of bacterial pneumonia, but one of these four patients did not have a positive culture despite collection of respiratory and blood cultures. Our recorded 30-day incidence of bacterial co-infection may therefore be an underestimate, reflecting the poor sensitivity of lower respiratory cultures in the setting of empiric antimicrobial therapy.

Bacterial co-infection was associated with higher mortality. This is despite the fact that 92.1% of our cohort received antibacterial drugs during hospitalization. The pathogenesis of influenza and bacterial co-infection is synergistic and complex. The disease process involves numerous viral and bacterial virulence factors interacting with the host immune system and adversely affecting respiratory physiology. In pandemic seasons, compared with usual epidemic seasons, a high proportion of the mortality from influenza infection, often complicated by bacterial co-infection, occurs in young, previously healthy people as a result of an aberrant immune response to the virus [@bib0115].

*S. aureus* was the most common species isolated in our cohort. In a 2009 study on co-infections in severely ill patients with influenza A (H1N1) pdm09 infection in 35 U.S. ICUs, *S. aureus* was also found to be the most common bacterial pathogen [@bib0050]. *S. pneumoniae*, *H. influenzae* and *S. pyogenes* were all also present among community-acquired pathogens but surprisingly, *P. aeruginosa* was more common than any of these species. *P. aeruginosa* is increasingly being described as a co-pathogen with influenza [@bib0120]. As expected, we recorded a high prevalence of Gram negative co-infections among hospital-acquired infections. In our cohort 31.3% of hospital-acquired co-infections were due to *S. aureus* and 19.4% were due to each *Pseudomonas* species and *Enterobacteriaceae*. In studies evaluating the agents of hospital-acquired bacterial pneumonia without an underlying influenza infection, 14--28% have been attributed to *S. aureus*, 16--34% have been attributed to *P. aeruginosa* and 19--35% have been attributed to *Enterobacteriaceae* [@bib0125]. The prevalence of *S. aureus* among hospital-acquired bacterial co-infections in our cohort was slightly higher than what would be expected in patients without influenza infection.

Co-infection resulted in greater resource allocation as measured by hospital length of stay and ICU length of stay in bivariable but not multivariable analysis. Moreover, time from symptom onset to administration of an antiviral effective against influenza was delayed in co-infected patients in bivariable but not multivariable analysis. A number of studies have shown an association between early effective antiviral use in influenza infection and reduced ICU admission and mortality, suggesting that the delay in our cohort may have been detrimental [@bib0130].

Risk factors for bacterial co-infection included lack of cardiovascular disease as well as leukocytosis and increased SOFA score on ICU admission. It is unclear why cardiovascular disease appeared to be protective in our cohort; it may be that statin use confers anti-inflammatory and immunomodulatory effects that may reduce risk of co-infection. This possible association warrants further study.

Viral co-infection was associated with increased mortality in our cohort in bivariable but not in multivariable analysis when controlling for underlying comorbidities. Studies evaluating this previously have been mixed [@bib0135], [@bib0140], [@bib0145]. The association between viral co-infection and mortality require further research.

Our study had several limitations. The majority of subjects were treated at U.S. tertiary care centers; thus, our findings may not be generalizable to any population of severely ill influenza patients. We did not include subjects admitted after April 1, 2014. Therefore, we did not include the final part of the influenza season, likely excluding disproportionately patients with severe influenza B infection, who may experience a different risk of bacterial and viral co-infection from influenza A (H1N1) pdm 09 patients. Management of patients and bacterial identification and susceptibility testing was not standardized. Rapid diagnostic testing may have resulted in some missed cases of influenza among ICU patients. However, this was the sole method used in only 3 of 33 studied hospitals. While we used a standardized data collection form, some variables were not available for some subjects. Finally, as a retrospective study, selection bias and immortal time bias may have affected our choice of subjects and our analysis, respectively.

This study highlights the importance of bacterial co-infection in the pathogenesis of severe influenza infection. Preventive measures to address co-infection include ensuring high rates of influenza, *S. pneumoniae* and *H. influenzae* vaccination, appropriate timing of antivirals and early and appropriate antibiotic therapy targeting MRSA and *Pseudomonas*. Therapy targeting MRSA particularly in cases of community-acquired pneumonia is important. Understanding the complex and synergistic relationship between bacteria and influenza is vital in decreasing mortality in future seasonal and pandemic influenza seasons.

Competing interests {#sec0040}
===================

None.

Funding {#sec0045}
=======

This publication was made possible in part by Grant Number D33HP25768 from the Health Resources and Services Administration (HRSA).

Ethical approval {#sec0050}
================

IRB approval received from UofC (IRB 14-0383) and each participating hospital.

[^1]: When there are missing data for a specific variable, the n for subjects with data on this variable is indicated in the far left column.

[^2]: Defined as either a respiratory fluoroquinolone (levofloxacin or moxifloxacin) or a combination of a broad-spectrum beta-lactam drug (ceftriaxone, cefepime, ampicillin-sulbactam, piperacillin-tazobactam, carbapenems) and azithromycin.

[^3]: Defined as combination therapy targeting methicillin resistant *S. aureus* (MRSA), which includes vancomycin or linezolid, and a second agent targeting *Pseudomonas aeruginosa*, which includes piperacillin-tazobactam, ceftazidime, cefepime, carbapenems (with the exception of ertapenem), aztreonam, ciprofloxacin, levofloxacin and colistin.

[^4]: Specific bacterial species not listed include *Escherichia coli* (N = 7), *Enterobacter cloacae* (N = 3), *Klebsiella pneumoniae* (N = 5), *Klebsiella oxytoca* (N = 1), *Serratia marcescens* (N = 1), *Citrobacter freundii* (N = 1), *Enterobacter gergoviae* (N = 1), *Proteus mirabilis* (N = 1), *Pseudomonas aeruginosa* (N = 17), *Pseudomonas fluorescens* (N = 1), *Enterococcus faecium* (N = 3), *Enterococcus faecalis* (N = 2), *Streptococcus mitis* (N = 2), *Streptococcus parasanguinis* (N = 1), *Streptococcus salivarius* (N = 1), *Staphylococcus epidermidis* (N = 3) and *Corynebacterium striatum* (N = 1).

[^5]: *Abbreviations*: CI, confidence intervals; SNF, skilled nursing facility; LTEC, long-term extended care facility; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; FTT, failure to thrive; SOFA, Sequential Organ Failure Assessment; ICU, Intensive Care Unit; sd, standard deviation.

[^6]: The multivariable analysis included all variables with p \< 0.05 in the bivariable analysis.

[^7]: When there are missing data for a specific variable, the n for subjects with data on this variable is indicated in the far left column.

[^8]: SOFA score is determined by the following laboratory or clinical criteria: PaO~2~/FiO~2~; Glasgow coma scale; mean arterial pressure or requiring administration of vasopressor; bilirubin; platelet count; creatinine or urine output.

[^9]: Determined by data abstracter by visual review of chest X-ray.
